Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of PRX-115 with or without methotrexate in adults with gout
MOH_2025-11-11_015452Phase 2Recruiting
- Sponsor
- Protalix BioTherapeutics
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of prx-115 and methotrexate in gout (6 arms), sponsored by Protalix BioTherapeutics. Primary endpoint: Reduction of serum urate during month 6. Started Oct 2025; status: recruiting.
02
Drugs
prx-115methotrexate
03
Conditions
gout
Beyond the preview
Go deeper on MOH_2025-11-11_015452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-11_015452.